These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24518498)

  • 1. Advanced digestive neuroendocrine tumors: metastatic pattern is an independent factor affecting clinical outcome.
    Panzuto F; Merola E; Rinzivillo M; Partelli S; Campana D; Iannicelli E; Pilozzi E; Mercantini P; Rossi M; Capurso G; Scarpa A; Cascinu S; Tomassetti P; Falconi M; Delle Fave G
    Pancreas; 2014 Mar; 43(2):212-8. PubMed ID: 24518498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors.
    Panzuto F; Campana D; Fazio N; Brizzi MP; Boninsegna L; Nori F; Di Meglio G; Capurso G; Scarpa A; Dogliotti L; De Braud F; Tomassetti P; Delle Fave G; Falconi M
    Neuroendocrinology; 2012; 96(1):32-40. PubMed ID: 22205326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognoses of GEP-NETS with undetermined malignant potentials of their primary sites.
    Kudo A; Ban D; Akashi T; Kumagai J; Aihara A; Inokuchi M; Kojima K; Kawano T; Tanaka S; Arii S
    Hepatogastroenterology; 2012 Sep; 59(118):1682-6. PubMed ID: 22584425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases.
    Hur S; Chung JW; Kim HC; Oh DY; Lee SH; Bang YJ; Kim WH
    J Vasc Interv Radiol; 2013 Jul; 24(7):947-56; quiz 957. PubMed ID: 23602421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.
    Panzuto F; Merola E; Pavel ME; Rinke A; Kump P; Partelli S; Rinzivillo M; Rodriguez-Laval V; Pape UF; Lipp R; Gress T; Wiedenmann B; Falconi M; Delle Fave G
    Oncologist; 2017 Apr; 22(4):409-415. PubMed ID: 28232598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification.
    Yang Z; Tang LH; Klimstra DS
    Am J Surg Pathol; 2011 Jun; 35(6):853-60. PubMed ID: 21566513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neuroendocrine neoplasm of digestive system with different grades: a clinicopathologic and prognostic study].
    Zhang MH; Liu YH; Luo XL; Lin XT; Zhuang HG
    Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):448-51. PubMed ID: 22932454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors.
    Dhall D; Mertens R; Bresee C; Parakh R; Wang HL; Li M; Dhall G; Colquhoun SD; Ines D; Chung F; Yu R; Nissen NN; Wolin E
    Hum Pathol; 2012 Apr; 43(4):489-95. PubMed ID: 21937080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.
    Gupta S; Johnson MM; Murthy R; Ahrar K; Wallace MJ; Madoff DC; McRae SE; Hicks ME; Rao S; Vauthey JN; Ajani JA; Yao JC
    Cancer; 2005 Oct; 104(8):1590-602. PubMed ID: 16134179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver-directed therapy for neuroendocrine neoplasm hepatic metastasis prolongs survival following progression after initial surgery.
    Saxena A; Chua TC; Zhao J; Morris DL
    J Surg Oncol; 2012 Mar; 105(4):342-50. PubMed ID: 22006355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin.
    Auernhammer CJ; Göke B
    Gut; 2011 Jul; 60(7):1009-21. PubMed ID: 21378384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
    Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
    Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing the surgical effort in patients with advanced neuroendocrine neoplasm hepatic metastases: a critical analysis of 40 patients treated by hepatic resection and cryoablation.
    Saxena A; Chua TC; Chu F; Al-Zahrani A; Morris DL
    Am J Clin Oncol; 2012 Oct; 35(5):439-45. PubMed ID: 21654315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life.
    Faggiano A; Carratù AC; Guadagno E; Tafuto S; Tatangelo F; Riccardi F; Mocerino C; Palmieri G; Damiano V; Siciliano R; Leo S; Mauro A; Tozzi LF; Battista C; De Rosa G; Colao A
    Oncotarget; 2016 Feb; 7(5):5538-47. PubMed ID: 26701729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes.
    Hallet J; Law CH; Cukier M; Saskin R; Liu N; Singh S
    Cancer; 2015 Feb; 121(4):589-97. PubMed ID: 25312765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical course of neuroendocrine tumors with different origins (the pancreas, gastrointestinal tract, and lung).
    Kim SJ; Kim JW; Oh DY; Han SW; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ
    Am J Clin Oncol; 2012 Dec; 35(6):549-56. PubMed ID: 21659833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variability of Ki67 labeling index in multiple neuroendocrine tumors specimens over the course of the disease.
    Singh S; Hallet J; Rowsell C; Law CH
    Eur J Surg Oncol; 2014 Nov; 40(11):1517-22. PubMed ID: 25088936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neuroendocrine tumors of digestive system: morphologic spectrum and cell proliferation (Ki67 index)].
    Delektorskaia VV; Kushliskiĭ NE
    Vestn Ross Akad Med Nauk; 2013; (5):28-37. PubMed ID: 24000665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinicopathological features and multivariate analysis of prognostic factors for patients with gastroenteropancreatic neuroendocrine tumors].
    Wang X; Song ZF; Yao WX; Pan CC; Xiang MF; Wang H
    Zhonghua Yi Xue Za Zhi; 2013 May; 93(18):1411-4. PubMed ID: 24025507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.